Pharming Group (PHAR)
8.89
-0.54
(-5.73%)
USD |
NASDAQ |
May 22, 10:46
Pharming Group Cash from Financing (TTM): -0.88M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -0.88M |
December 31, 2023 | -1.039M |
September 30, 2023 | 0.259M |
June 30, 2023 | -6.901M |
March 31, 2023 | -4.723M |
December 31, 2022 | -4.982M |
September 30, 2022 | -5.475M |
June 30, 2022 | -6.275M |
March 31, 2022 | -28.46M |
December 31, 2021 | -27.95M |
September 30, 2021 | -28.83M |
June 30, 2021 | -25.54M |
March 31, 2021 | -1.781M |
December 31, 2020 | 60.69M |
September 30, 2020 | 46.83M |
June 30, 2020 | 39.98M |
March 31, 2020 | 27.90M |
December 31, 2019 | -63.47M |
September 30, 2019 | -57.40M |
June 30, 2019 | -61.96M |
March 31, 2019 | -53.96M |
December 31, 2018 | -20.55M |
September 30, 2018 | -18.22M |
June 30, 2018 | -4.701M |
March 31, 2018 | -3.119M |
Date | Value |
---|---|
December 31, 2017 | -3.905M |
September 30, 2017 | 75.19M |
June 30, 2017 | 71.37M |
March 31, 2017 | 72.46M |
December 31, 2016 | 70.81M |
September 30, 2016 | -2.097M |
June 30, 2016 | 15.86M |
March 31, 2016 | 16.14M |
December 31, 2015 | 16.44M |
September 30, 2015 | 15.16M |
June 30, 2015 | -3.078M |
March 31, 2015 | 16.12M |
December 31, 2014 | 21.88M |
September 30, 2014 | 33.52M |
June 30, 2014 | 34.82M |
March 31, 2014 | 15.33M |
December 31, 2013 | 29.12M |
September 30, 2013 | 22.79M |
June 30, 2013 | 25.58M |
March 31, 2013 | 25.03M |
December 31, 2012 | 15.30M |
September 30, 2012 | 10.43M |
June 30, 2012 | 10.67M |
March 31, 2012 | 12.21M |
December 31, 2011 | 16.40M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-63.47M
Minimum
Dec 2019
60.69M
Maximum
Dec 2020
-7.500M
Average
-5.228M
Median
Cash from Financing (TTM) Benchmarks
uniQure NV | 362.59M |
ProQR Therapeutics NV | -2.640M |
Merus NV | 260.02M |
argenx SE | -- |
Pharvaris NV | 353.20M |